4,577 results match your criteria American journal of clinical oncology[Journal]


Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.

Am J Clin Oncol 2019 Feb 15. Epub 2019 Feb 15.

Radiation Oncology, Vanderbilt University, Nashville, TN.

Purpose: Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation, and platinum agents. We conducted a phase IB trial to determine the recommended phase II dose of everolimus with carboplatin and radiation.

Materials And Methods: Patients with stage II/III esophageal cancer were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000524DOI Listing
February 2019

Incidence of Neonatal Neutropenia and Leukopenia After In Utero Exposure to Chemotherapy for Maternal Cancer.

Am J Clin Oncol 2019 Feb 15. Epub 2019 Feb 15.

Cooper Medical School at Rowan University, Camden, NJ.

Objective: The main purpose of this article was to report the incidence of neonatal neutropenia or leukopenia after chemotherapy exposure during pregnancy according to the time elapsed between treatment during pregnancy and birth.

Background: A single study reports 33% of infants exposed to chemotherapy within the last month of pregnancy are born with neutropenia, which can place the newborn at risk for nosocomial infections. On the basis of this report, chemotherapy is typically stopped by 34 weeks of pregnancy to avoid maternal or neonatal myelosuppression at delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000527DOI Listing
February 2019

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).

Am J Clin Oncol 2019 Feb 15. Epub 2019 Feb 15.

University of Kentucky, Lexington, KY.

Background: Eribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels.

Methods: In a multicenter ECOG trial, patients with progressive metastatic CRPC, ECOG 0-2 were treated with eribulin 1.4 mg/m as an IV bolus over 5 minutes on days 1 and 8 of a 21-day cycle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000526DOI Listing
February 2019

Effects of Social and Contextual Factors Including Marital Status and Children on the Use of Palliative Chemotherapy in Metastatic Colorectal Cancer.

Am J Clin Oncol 2019 Feb 15. Epub 2019 Feb 15.

Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK Canada.

Background: There is evidence that social and contextual factors such as living alone are associated with outcomes in cancer patients. However, little is known about their influence on the use of palliative chemotherapy in metastatic colorectal cancer (mCRC). In this study, we examined social and contextual factors, including marital status, having children, and distance to a cancer center, for their association with the use of chemotherapy in patients with mCRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000530DOI Listing
February 2019

Concurrent Versus Sequential Chemoradiation for Low-grade Gliomas Meeting RTOG 9802 Criteria.

Am J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Departments of Radiation Oncology.

Purpose: Radiation Therapy Oncology Group (RTOG) 9802 has established postoperative radiation therapy (RT) and chemotherapy sequentially as the new standard of care for patients with high-risk low-grade glioma (LGG) meeting trial criteria. Although this trial investigated sequential chemoradiation therapy (sCRT) with RT followed by chemotherapy, it is unknown whether concurrent chemoradiation therapy (cCRT) may offer advantages over sCRT.

Materials And Methods: The National Cancer Database (NCDB) was queried for newly diagnosed World Health Organization (WHO) grade II glioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000519DOI Listing
February 2019
1 Read

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.

Am J Clin Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA.

Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangements are observed in about 4% to 8% non-small cell lung cancer (NSCLC). ALK+ tumors have been associated with increased pleural and pericardial disease. Our primary objective was to determine the uncommon sites of metastasis of ALK+ NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000508DOI Listing
February 2019
1 Read

Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion.

Am J Clin Oncol 2019 Feb 6. Epub 2019 Feb 6.

Departments of Radiation Oncology.

Objectives: Patients with hepatocellular carcinoma (HCC) and gross vascular invasion (GVI) have poor outcomes with systemic therapy such as sorafenib. Both external beam radiation therapy (EBRT) and transarterial radioembolization (TARE) have been utilized for this patient population. We sought to compare outcomes using dual modality radiation (EBRT+TARE) versus EBRT alone in patients with HCC and GVI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000523DOI Listing
February 2019
2.611 Impact Factor

Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer.

Am J Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Surgical Oncology.

Objectives: The main objectives of this study were to prospectively evaluate the safety and efficacy of stereotactic body radiation therapy (SBRT) in the neoadjuvant setting for resectable or borderline resectable pancreatic cancer.

Materials And Methods: Eighteen patients were enrolled from November 2014 to June 2017. Following 3 cycles of chemotherapy, SBRT was delivered to the tumor and abutting vessel and a 3 mm planning target volume (PTV) margin to 33 Gy (6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000518DOI Listing
February 2019
1 Read

Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.

Am J Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Radiation Oncology, Beaumont Hospital, Dearborn, MI.

Objectives: We applied an established prognostic model to high-risk prostate cancer (HRPC) patients treated with radiotherapy (RT) and evaluated the influence of clinical and treatment variables on treatment outcomes.

Methods: In total, 1075 HRPC patients undergoing definitive radiotherapy (RT) between 1995 and 2010 were retrospectively reviewed. Median follow-up was 62. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000521DOI Listing
February 2019
2 Reads

Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma.

Am J Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Departments of Surgical Oncology.

Introduction: Chemoradiotherapy and surgery are the basis of the potentially curative treatment for esophageal cancer. Approximately 1 in 5 patients, however, do not benefit from this intensive treatment due to early treatment failure. The aim of this study was to evaluate levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 at diagnosis, in relation to survival and early treatment failure (disease recurrence or death within 1 year after surgery). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000525DOI Listing
February 2019

Tobacco Treatment Programs at National Cancer Institute-designated Cancer Centers: A Systematic Review and Online Audit.

Am J Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins Medical Institutions.

Objectives: The main objectives of this study were to evaluate abstinence rates of tobacco treatment programs (TTPs) at National Cancer Institute (NCI)-designated cancer centers (DCCs) and to ascertain the number of NCI-DCCs with online references to TTPs.

Methods: Literature searches of Pubmed, EMBASE, Web of Science, and Scopus were performed from their inception through January 2018 using keywords including cancer patients, cancer survivors, tobacco, smoking, cessation, and program. In total, 4094 articles were identified, 1450 duplicates were removed, 2644 candidate titles and abstracts were screened, and 210 selected full-text articles were independently reviewed by 2 authors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000522DOI Listing
February 2019

Reply to Elmali and Colleagues.

Am J Clin Oncol 2019 Feb;42(2):228-229

Department of Radiation Oncology, College of Medicine, University of Florida, Gainesville, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000502DOI Listing
February 2019

A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer.

Am J Clin Oncol 2019 Jan 22. Epub 2019 Jan 22.

Department of Radiation Oncology.

Purpose/objective(s): Management of localized high-risk prostate cancer remains challenging. At our institution we performed a prospective phase II study of 2 years of androgen deprivation therapy (ADT), pelvic radiation, Cesium (Cs)-131 brachytherapy boost, and adjuvant docetaxel in high risk, localized prostate cancer with a primary endpoint of 3-year disease-free survival.

Materials/methods: Acute/chronic hematologic, gastrointestinal (GI) and genitourinary (GU) toxicities were scored based on the CTCAE v3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000520DOI Listing
January 2019
1 Read

Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis.

Am J Clin Oncol 2019 Jan 16. Epub 2019 Jan 16.

Departments of Surgery and Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto.

Objectives: Metformin has been associated with improved survival outcomes in various malignancies. However, studies in kidney cancer are conflicting. We performed a systematic review and meta-analysis to evaluate the association between metformin and kidney cancer survival. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00000421-900000000-9884
Publisher Site
http://dx.doi.org/10.1097/COC.0000000000000512DOI Listing
January 2019
6 Reads

Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved Community.

Am J Clin Oncol 2019 Jan 16. Epub 2019 Jan 16.

Oncology.

Background: Lack of access to primary care physicians (PCPs) may be an important contributor to mortality differences attributed to race/ethnicity. This study examined the effects of primary care access on mortality of lung cancer patients in an underserved community.

Methods: Medical records of all newly diagnosed patients with primary lung cancer from 2012 to 2016 at a National Cancer Institute (NCI)-designated center in Bronx, New York were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000516DOI Listing
January 2019
1 Read

Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia: A Meta-analysis of Randomized Controlled Trials.

Am J Clin Oncol 2019 Jan 8. Epub 2019 Jan 8.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore MD.

Introduction: Neutropenic diets are commonly prescribed to cancer patients with neutropenia with the intention of reducing rates of infection. These diets are restrictive and are associated with lower patient satisfaction and possibly malnutrition. Further, it is unclear if these restrictive diets are effective in reducing infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000514DOI Listing
January 2019
14 Reads

Extraskeletal Osteosarcomas: A Case Made for Combined Modality Local Therapy With Radiation and Surgery.

Am J Clin Oncol 2019 Jan 4. Epub 2019 Jan 4.

Departments of Radiation Oncology.

Objective: We evaluated our experience treating patients with extraskeletal osteosarcoma (ESOS) using combined modality local therapy, including surgery and radiation therapy (RT), to investigate local control (LC) and other survival endpoints.

Methods: We reviewed the records of 21 consecutive patients with nonmetastatic, ESOS treated with RT in combination with surgery at our institution from 1984 to 2015. Postoperative RT was used for 10 patients (48%) to a median dose of 60 Gy (range, 60 to 68 Gy). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000515DOI Listing
January 2019
4 Reads

Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.

Am J Clin Oncol 2019 Jan 2. Epub 2019 Jan 2.

Department of Medicine, University of British Columbia.

Objectives: Metastatic non-small cell lung cancer (NSCLC) has a poor prognosis. Most patients present with stage IV, and many patients treated curatively with stage I to III develop recurrent metastatic disease. It is unknown whether the natural history differs between patients with recurrent versus de novo metastatic NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000513DOI Listing
January 2019
17 Reads

Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer Center.

Am J Clin Oncol 2018 Dec 31. Epub 2018 Dec 31.

Department of Oncology, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, Detroit, MI.

Objectives: Adenocarcinoma of the pancreas represents the third leading cause of cancer-related death in the United States. Drug combinations, FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) and gemcitabine/nab-paclitaxel, showed a clinically meaningful benefit when compared with single-agent gemcitabine in phase III trials. The goal of this study was to investigate whether there was an increase in overall survival (OS) for patients treated for metastatic pancreatic cancer after the introduction of the above regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000507DOI Listing
December 2018
3 Reads

Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma.

Am J Clin Oncol 2018 Dec 27. Epub 2018 Dec 27.

Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA.

Introduction: Adjuvant management of anaplastic oligodendrogliomas (AOs) and anaplastic oligoastrocytomas (AOAs) is guided by 2 seminal phase III trials, one of which utilized radiotherapy (RT) followed by chemotherapy (CT) (RT-CT), and the other in which CT was followed by RT (CT-RT). Both paradigms are endorsed by the National Comprehensive Cancer Network because no direct comparison in the first-line (nonprogressive) setting has been performed to date. This study of a contemporary national database sought to evaluate practice patterns and outcomes between both approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000511DOI Listing
December 2018
1 Read

Factors Influencing Clinical and Setting Pathways After Discharge From an Acute Palliative/Supportive Care Unit.

Am J Clin Oncol 2018 Dec 27. Epub 2018 Dec 27.

Department of Sciences for Health Promotion and Mother Child Care, University of Palermo, Palermo, Italy.

Aim: The aim of this study was to assess the factors which influence the care pathway after discharge from an acute palliative supportive care unit (APSCU).

Methods: Patients' demographics, indications for admission, kind of admission, the presence of a caregiver, awareness of prognosis, data on anticancer treatments in the last 30 days, ongoing treatment (on/off or uncertain), the previous care setting, analgesic consumption, and duration of admission were recorded. The Edmonton Symptom Assessment Scale (ESAS) at admission and at time of discharge (or the day before death), CAGE (cut down, annoy, guilt, eye-opener), and the Memorial Delirium Assessment Scale (MDAS), were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000510DOI Listing
December 2018
2 Reads

Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.

Am J Clin Oncol 2018 Dec 14. Epub 2018 Dec 14.

Oregon Health & Science University, Portland, OR.

Objectives: The anti-CTLA-4 and antiprogrammed cell death-1 (PD-1) therapies have significantly improved survival of patients with metastatic melanoma. However, there is limited data regarding the interaction between immunotherapy (IT) and stereotactic radiosurgery (SRS) in patients with brain metastasis, particularly how combination therapy may affect toxicity and intracranial tumor control.

Methods: We retrospectively reviewed 26 patients with metastatic melanoma who received immune check point inhibitors and SRS for brain metastasis from 2011 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000509DOI Listing
December 2018
1 Read

Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma.

Am J Clin Oncol 2018 Dec 14. Epub 2018 Dec 14.

Division of Hematology/Oncology and GW Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC.

Multiple myeloma (MM) is a B-cell malignancy characterized by the abnormal proliferation of clonal plasma cells in the bone marrow leading to end-organ manifestations. Despite the advancement in the therapy and care of patients with MM, relapse and resistance to standard therapy remain significant. The development of immunotherapy as a treatment modality for many types of cancers has led investigators to explore its use in MM in order to elicit myeloma-targeted immune responses, especially given that immune dysregulation is an underlying feature in the pathogenesis and progression of MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000506DOI Listing
December 2018
1 Read

Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.

Am J Clin Oncol 2019 Feb;42(2):138-142

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology.

Background: The Multinational Association of Supportive Care of Cancer (MASCC) risk-index score has been validated as a stratification tool for febrile neutropenia (FN) risk in a heterogeneous group of cancer patients; recently, it has been deemed a suitable tool in gynecologic oncology patients in a retrospective study. This is a prospective multi-institutional study wherein we sought to validate MASCC score for stratifying FN morbidity in gynecologic oncology patients.

Methods: IRB approval was obtained at 4 institutions for prospective data collection of gynecologic cancer patients admitted with FN from 3/1/2013 to 9/1/2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345587PMC
February 2019
6 Reads

The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University.

Am J Clin Oncol 2019 Feb;42(2):166-171

Oncology.

Background: As a diagnosis of exclusion, Undifferentiated Pleomorphic Sarcoma (UPS) has unclear clinical characteristics. The objective of this retrospective cohort study is to investigate which clinical and prognostic factors of primary lower-extremity UPS will determine failure.

Methods: We retrospectively reviewed 55 primary lower-extremity UPS cases treated at Stanford between 1998 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000496DOI Listing
February 2019
1 Read

Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial.

Am J Clin Oncol 2019 Feb;42(2):221-227

Division of Functional Neurosurgery, Institute of Psychiatry-IPq, Hospital das Clinicas, FMUSP.

Background: Complete tumor removal by transsphenoidal surgery is usually difficult for large nonfunctioning pituitary adenomas (NFPAs). A validated medical treatment may be useful for their management. This study evaluates the clinical efficacy of the dopaminergic agonist cabergoline for residual NFPA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000505DOI Listing
February 2019
1 Read

Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.

Am J Clin Oncol 2019 Feb;42(2):190-195

Mayo Clinic, Rochester, MN.

Background: Our purpose was to evaluate the prognostic impact of pathologically confirmed esophageal adenosquamous carcinoma (ASC) and its association with HER2 status and clinicopathologic characteristics.

Methods: Among 796 patients with esophageal or gastroesophageal junction adenocarcinoma who underwent curative resection, surgical pathology reports were reviewed, and suspected ASC was confirmed utilizing p63 and CK5/6 immunostaining. HER2 status was determined using immunohistochemistry and fluorescence in situ hybridization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000495DOI Listing
February 2019
2 Reads

Concurrent Radiation and Immunotherapy: Survey of Practice Patterns in the United States.

Am J Clin Oncol 2019 Feb;42(2):208-214

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.

Objective: The objective of this study was to report on US radiation oncologists' (ROs) practice patterns and perceptions of concurrent radiation (RT) and immunotherapy (IT) (CRI).

Methods: A 22-question survey was emailed to radiation oncologists in February 2018. CRI was defined as RT completed within 1 week before initial IT infusion through 4 weeks after final IT infusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000501DOI Listing
February 2019
10 Reads

Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer.

Am J Clin Oncol 2019 Feb;42(2):196-201

Department of Oncology, Virginia Mason Cancer Institute, Seattle, WA.

Objectives: There is limited randomized data to guide second-line chemotherapy selection in advanced pancreatic cancer (APC). We aimed to characterize predictors and outcomes of second-line chemotherapy in patients with APC.

Methods: We identified all patients with APC [locally advanced (LAPC) or metastatic (MPC)] who received ≥1 cycle of first-line chemotherapy between January 2012 and December 2015 across 6 cancer centers in British Columbia, Canada. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000500DOI Listing
February 2019
2 Reads
2.611 Impact Factor

Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.

Am J Clin Oncol 2019 Feb;42(2):215-220

Department of Medical Oncology, Breast Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Objectives: To analyze differences in overall survival (OS) between male breast cancer (MBC) and female breast cancer (FBC) according to tumor subtype compared with other factors.

Materials And Methods: We evaluated men and women with breast cancer between 2010 and 2013 with known hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) status reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Patient characteristics were compared between groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000497DOI Listing
February 2019
1 Read

The Value of Prognostic Nutritional Index in Follicular Lymphoma.

Am J Clin Oncol 2019 Feb;42(2):202-207

Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hong Kong.

Objectives: Previous studies reported that prognostic nutritional index (PNI), a marker of host inflammatory and nutritional status, is associated with prognoses in a number of cancer types. Thus, we investigated PNI at diagnosis as a prognostic factor in FL.

Methods: We reviewed FL patients in Tuen Mun Hospital, Hong Kong from 2000 to 2014 (n=88). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000493DOI Listing
February 2019
9 Reads

Management of Unresectable T4b Esophageal Cancer: Practice Patterns and Outcomes From the National Cancer Data Base.

Am J Clin Oncol 2019 Feb;42(2):154-159

Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE.

Purpose: Patients with unresectable cT4b esophageal cancer (EC) are rare and largely excluded from prospective trials. As a result, current treatment recommendations are based on limited evidence. This study sought to evaluate national practice patterns and outcomes for this population and evaluated 3 primary cohorts: patients receiving chemotherapy (CT) with or without subtherapeutic radiotherapy (RT), definitive chemoradiotherapy (CRT), or CT with or without RT followed by definitive surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000499DOI Listing
February 2019
15 Reads
2.611 Impact Factor

Accelerated Hypofractionated Radiation Therapy for Elderly Frail Bladder Cancer Patients Unfit for Surgery or Chemotherapy.

Am J Clin Oncol 2019 Feb;42(2):179-183

Institute of Oncology.

Purpose/objectives: The main purpose of this study was to report treatment outcomes of definitive image-guided accelerated hypofractionated radiation therapy for elderly patients with muscle-invasive bladder cancer unsuitable for surgery or trimodality therapy.

Materials And Methods: Patients with confirmed muscle-invasive or high-risk T1 transitional cell carcinoma of the bladder, stage T1-T4aN0M0, who underwent transurethral resection of bladder tumor were irradiated with 45 Gy in 15 fractions. Comorbidity was assessed by Charlson Comorbidity Index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000491DOI Listing
February 2019
12 Reads

MGMT Testing in Glioblastomas: Pitfalls and Opportunities.

Am J Clin Oncol 2019 Feb;42(2):117-122

Division of Neurosurgery, University of Toronto, Toronto, Canada.

Gliomas, that do not respond to alkylating agent chemotherapy, can be made more sensitive to chemotherapy through promotor mediated epigenetic silencing of the MGMT gene. MGMT is one of the important markers in glioblastomas as it not only predicts response to therapy but may also be used as an independent prognostic marker. As such, MGMT is gaining increasing traction in diagnosis, prognostication, and therapeutic decision-making for these highly malignant gliomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000490DOI Listing
February 2019
21 Reads
2.611 Impact Factor

Role of Stereotactic Body Radiation Therapy in Early Stage Small Cell Lung Cancer in the Era of Lung Cancer Screening: A Systematic Review.

Am J Clin Oncol 2019 Feb;42(2):123-130

Department of Radiation Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.

With the obvious benefit from low dose computed tomography to reduce the lung cancer-specific mortality, lung cancer screening is on the rise. With the implementation of the screening programs, diagnosis of early stage lung cancer is expected to increase, and small cell lung cancer (SCLC) would account for 10% of screen-detected lung cancer. Apart from Concurrent chemoradiation (CRT), the present guidelines virtually do not support other options for radiation (RT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000489DOI Listing
February 2019
8 Reads
2.611 Impact Factor

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.

Am J Clin Oncol 2019 Feb;42(2):184-189

Department of Oncology, Mayo Clinic, Rochester, MN.

Objectives: Preclinical studies demonstrated antitumor activity of dovitinib in pancreatic cancer models. This phase Ib study aimed to determine the maximum tolerated dose (MTD) of dovitinib in combination with gemcitabine and capecitabine and to characterize the safety and pharmacokinetic profile in patients with advanced pancreatic and biliary tract cancers and solid malignancies.

Materials And Methods: Patients received gemcitabine 1000 mg/m² intravenously on days 1 and 8, capecitabine 1300 mg/m² oral daily from day 1 to 14, and dovitinib oral daily 5 days on and 2 days off, every 21-day cycle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000492DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345595PMC
February 2019
2 Reads
2.611 Impact Factor

An Evaluation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) Staging System for Retroperitoneal Sarcomas Using the National Cancer Data Base (NCDB): Does Size Matter?

Am J Clin Oncol 2019 Feb;42(2):160-165

University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX.

Objectives: Retroperitoneal sarcomas (RPS) are often large at diagnosis calling into question the seventh edition AJCC size classification of <5 cm (T1) or ≥5 cm (T2). The eighth edition expands T stage into 4 categories (T1: ≤5 cm, T2: 515 cm). We evaluated the prognostic ability of the eighth edition using the National Cancer Database (NCDB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000486DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345601PMC
February 2019
1 Read

Factors Associated With Head and Neck Cancer Hospitalization Cost and Length of Stay-A National Study.

Am J Clin Oncol 2019 Feb;42(2):172-178

Department of Epidemiology and Biostatistics, Saint Louis University College for Public Health and Social Justice.

Objectives: The aim of the study was to estimate hospitalization cost, and factors associated with hospitalization costs and length of stay (LOS) of patients treated for head and neck cancer in the United States.

Methods: Data on 71,440 weighted hospital admissions from the 2014 National Inpatient Sample with a diagnosis of head and neck cancer were examined. Multivariable linear regression models estimated factors associated with hospitalization costs, and negative binomial regression models were used to identify factors associated with hospital LOS. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00000421-900000000-9887
Publisher Site
http://dx.doi.org/10.1097/COC.0000000000000487DOI Listing
February 2019
9 Reads

How to Optimize Cancer Treatment in Older Patients: An Overview of Available Geriatric Tools.

Am J Clin Oncol 2019 Feb;42(2):109-116

University Paris-Est, UPEC, DHU A-TVB, IMRB-EA 7376 CEpiA (Clinical Epidemiology and Ageing Unit).

Cancer is a disease of older people, but this age group has often been excluded from clinical trials of cancer, which leads to poor transportability of standardized treatments in older cancer patients. One of the main reasons for the exclusion is the heterogeneity of older people in several domains: social environment, comorbidities, dependency, functional status, nutritional status, cognition status, and mood status. Comprehensive geriatric assessment aims to assess this heterogeneity and has identified frequent health problems often unknown before therapeutic decisions, which allows for targeted geriatric interventions with or without follow-up and appropriate cancer treatment selection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000488DOI Listing
February 2019
2 Reads

Factors Affecting Racial Disparities in End-of-Life Care Costs Among Lung Cancer Patients: A SEER-Medicare-based Study.

Am J Clin Oncol 2019 Feb;42(2):143-153

Division of Pulmonary Critical Care & Sleep Medicine, The University of Texas Medical Branch, Galveston, TX.

Objectives: Racial disparities exist in end-of-life lung cancer care, which could potentially lead to considerable racial differences in end-of-life care costs. This study for the first time estimates the racial differences in end-of-life care costs among lung cancer patients, and identifies and quantifies factors that contribute the most to these differences using a statistical decomposition method.

Methods: This is a retrospective analysis of patients 66 years and older, diagnosed with stage I-IV lung cancer, who died on or before December 31, 2013, using the Surveillance Epidemiology and End Result-Medicare data from 1991 to 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000485DOI Listing
February 2019
1 Read

A Simplified Risk Stratification Method for Women With Stage I Endometrial Carcinoma.

Am J Clin Oncol 2019 Feb;42(2):131-137

Women's Health Services, Division of Gynecologic Oncology.

Objectives: Available risk stratification methods for women with endometrial carcinoma are controversially defined. We sought to develop a simplified and an individualized prognostic index for cancer recurrence in women with International Federation of Gynecology and Obstetrics (FIGO) stage I endometrial carcinoma, solely of endometrioid histology.

Materials And Methods: We identified 976 women who underwent a hysterectomy and did not receive any adjuvant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000484DOI Listing
February 2019
2 Reads

Challenging the Requirement to Treat the Contralateral Neck in Cases With >4 mm Tumor Thickness in Patients Receiving Postoperative Radiation Therapy for Squamous Cell Carcinoma of the Oral Tongue or Floor of Mouth.

Am J Clin Oncol 2019 Jan;42(1):89-91

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL.

Hypothesis: While treating patients with postoperative radiotherapy (RT) for squamous cell carcinoma of the oral tongue or floor of mouth, we hypothesized a low risk of tumor recurrence in the contralateral neck in the absence of contralateral neck RT when the primary tumor is >1 cm from the midline regardless of tumor thickness (TT) or depth of invasion (DOI)>4 mm.

Objective: The policy at our institution for many years has been to limit postoperative RT to the ipsilateral side when the primary tumor does not cross the midline, regardless of TT or DOI. We report the rate of isolated contralateral neck failure in this group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000480DOI Listing
January 2019
1 Read

Patterns of Care and Outcomes of Elderly Esophageal Cancer Patients Not Meeting Age-based Criteria of the CROSS Trial.

Am J Clin Oncol 2019 Jan;42(1):67-74

Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE.

Objectives: The CROSS trial established neoadjuvant chemoradiation followed by surgery (nCRT-S) as superior to surgery alone (S) for locally advanced esophageal cancer (EC). However, because patients above 75 years of age were excluded, this comparison cannot be extrapolated to older patients. This study of a large, contemporary national database evaluated practice patterns in elderly patients ineligible for CROSS, and analyzed overall survival (OS) between nCRT+S, S, and definitive CRT (dCRT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000481DOI Listing
January 2019
1 Read

Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.

Am J Clin Oncol 2019 Jan;42(1):75-81

Department of Oncology, University of Calgary, Cumming School of Medicine.

Objectives: To compare the clinical characteristics and outcomes between relapsed and de novo metastatic non-small cell lung cancer (NSCLC).

Materials And Methods: We reviewed all NSCLC diagnoses between January 1999 and December 2013 in the institutional Glans-Look Lung Cancer Database, which contains demographic, clinical, pathologic, treatment, and outcome information. Patients with distant metastasis at diagnosis (American Joint Committee on Cancer [AJCC] eighth edition, stage IV), the "de novo" cohort, were compared with the "relapsed" cohort, consisting of patients diagnosed with early stage disease (stage I/II) undergoing curative intent treatment and subsequently experiencing metastatic relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000483DOI Listing
January 2019
6 Reads

Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival.

Am J Clin Oncol 2019 Jan;42(1):82-88

Department of Radiation Oncology.

Objectives: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with higher incidence among whites, elderly, and immunosuppressed patients. Although immunosuppressed MCC patients are at higher risk of recurrence and MCC-related death, it is unknown whether immunosuppression type is associated with differential outcomes.

Materials And Methods: We retrospectively evaluated 89 nonmetastatic MCC patients with a diagnosis of chronic immunosuppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000482DOI Listing
January 2019
2 Reads

Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program.

Am J Clin Oncol 2019 Jan;42(1):42-45

Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan.

Objective: The activity of cabozantinib in nonclear cell histologies has not been evaluated.

Materials And Methods: Data were collected across 24 Italian hospitals. Patients were aged 18 years and older with advanced nonclear cell renal cell carcinoma (RCC), with an Eastern Cooperative Oncology Group Performance Status 0 to 2, who had relapsed after previous systemic treatments for metastatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000478DOI Listing
January 2019
4 Reads

Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.

Am J Clin Oncol 2019 Jan;42(1):99-106

Department of Nuclear Medicine/Radiology, University of Michigan Hospital.

Painful osseous metastasis resulting from castration-resistant prostate carcinoma is a common clinical problem. Historically, nuclear medicine offered several palliative beta-emitting radiopharmaceuticals targeting the skeleton with the goal of decreasing pain. However, these have largely been replaced by the alpha-emitting agent radium (Ra). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000479DOI Listing
January 2019
3 Reads

Survival Benefit of Adjuvant Radiation Therapy in Node-positive Vulvar Cancer.

Am J Clin Oncol 2018 Sep;41(9):845-850

Departments of Radiation Oncology.

Background: Adjuvant radiation therapy improves overall survival in patients with vulvar cancer with 2+ positive lymph nodes, but its benefit remains uncertain for 1 positive lymph node.

Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified node-positive, American Joint Committee on Cancer version 6-staged women with squamous cell vulvar carcinoma treated with and without radiation following surgery. The Kaplan-Meier approach assessed overall and cause-specific survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000393DOI Listing
September 2018
3 Reads